KLRD1 and myeloid sarcoma: Patients suffering from multiple sclerosis (MS) display HLA-E+ oligodendrocytes and NKG2C+CD4+ T cells, therefore, targeting the CD94/NKG2C receptor may be considered in future development of MS therapies (Zaguia et al. 2013).